TY - JOUR T1 - Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. AU - Rodriguez-Morales,Alfonso J, AU - Cardona-Ospina,Jaime A, AU - Gutiérrez-Ocampo,Estefanía, AU - Villamizar-Peña,Rhuvi, AU - Holguin-Rivera,Yeimer, AU - Escalera-Antezana,Juan Pablo, AU - Alvarado-Arnez,Lucia Elena, AU - Bonilla-Aldana,D Katterine, AU - Franco-Paredes,Carlos, AU - Henao-Martinez,Andrés F, AU - Paniz-Mondolfi,Alberto, AU - Lagos-Grisales,Guillermo J, AU - Ramírez-Vallejo,Eduardo, AU - Suárez,Jose A, AU - Zambrano,Lysien I, AU - Villamil-Gómez,Wilmer E, AU - Balbin-Ramon,Graciela J, AU - Rabaan,Ali A, AU - Harapan,Harapan, AU - Dhama,Kuldeep, AU - Nishiura,Hiroshi, AU - Kataoka,Hiromitsu, AU - Ahmad,Tauseef, AU - Sah,Ranjit, AU - ,, Y1 - 2020/03/13/ PY - 2020/02/29/received PY - 2020/03/11/revised PY - 2020/03/11/accepted PY - 2020/3/18/pubmed PY - 2020/5/19/medline PY - 2020/3/18/entrez KW - Clinical features KW - Coronavirus disease 2019 KW - Epidemic KW - Laboratory KW - Outcomes KW - SARS-CoV-2 SP - 101623 EP - 101623 JF - Travel medicine and infectious disease JO - Travel Med Infect Dis VL - 34 N2 - INTRODUCTION: An epidemic of Coronavirus Disease 2019 (COVID-19) began in December 2019 in China leading to a Public Health Emergency of International Concern (PHEIC). Clinical, laboratory, and imaging features have been partially characterized in some observational studies. No systematic reviews on COVID-19 have been published to date. METHODS: We performed a systematic literature review with meta-analysis, using three databases to assess clinical, laboratory, imaging features, and outcomes of COVID-19 confirmed cases. Observational studies and also case reports, were included, and analyzed separately. We performed a random-effects model meta-analysis to calculate pooled prevalences and 95% confidence intervals (95%CI). RESULTS: 660 articles were retrieved for the time frame (1/1/2020-2/23/2020). After screening, 27 articles were selected for full-text assessment, 19 being finally included for qualitative and quantitative analyses. Additionally, 39 case report articles were included and analyzed separately. For 656 patients, fever (88.7%, 95%CI 84.5-92.9%), cough (57.6%, 95%CI 40.8-74.4%) and dyspnea (45.6%, 95%CI 10.9-80.4%) were the most prevalent manifestations. Among the patients, 20.3% (95%CI 10.0-30.6%) required intensive care unit (ICU), 32.8% presented with acute respiratory distress syndrome (ARDS) (95%CI 13.7-51.8), 6.2% (95%CI 3.1-9.3) with shock. Some 13.9% (95%CI 6.2-21.5%) of hospitalized patients had fatal outcomes (case fatality rate, CFR). CONCLUSION: COVID-19 brings a huge burden to healthcare facilities, especially in patients with comorbidities. ICU was required for approximately 20% of polymorbid, COVID-19 infected patients and hospitalization was associated with a CFR of >13%. As this virus spreads globally, countries need to urgently prepare human resources, infrastructure and facilities to treat severe COVID-19. SN - 1873-0442 UR - https://www.unboundmedicine.com/medline/citation/32179124/Clinical_laboratory_and_imaging_features_of_COVID_19:_A_systematic_review_and_meta_analysis_ DB - PRIME DP - Unbound Medicine ER -